YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Currency-US Dollar Up] ModernLife Eledon Pharmaceuticals (ELDN [https://seekingalpha.com/symbol/ELDN]) traded higher on Tuesday after updating long-term data from a mid-stage trial for its lead candidate, tegoprubart, and announcing the F…
Issued on behalf of Avaí Bio, Inc. (OTCQB: AVAI) LAS VEGAS, July 21, 2026 /PRNewswire/ -- (American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been th…
(RTTNews) - This week, the biotech sector delivered a mix of FDA and EU approvals, strategic reorganizations, layoff, acquisitions, and late-stage clinical readouts across oncology, metabolic disease, neurology and immunology. Regulatory m…
(RTTNews) - Natera, Inc. (NTRA), a clinical-stage company in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (ELDN), a clinical-stage biotechnology company developing immune-modulating therapies, have entered into a…
Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon's planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026 AUSTIN, Texas & IRVINE, Calif., Ju…
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Eledon Pharmaceuticals, Inc. (ELDN) been one of those stocks this year? A quick glance at the compan…
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, hinting at possible breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. Price swings ahead of the…
NewcelX Ltd. reported its 2025 financial results, with leadership emphasizing a "transformative year" marked by merger completion, balance sheet improvements, and progress in its lead Type 1 diabetes program, NCEL-101. Ronen Twito, executi…
Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the 10 Unstoppable Stocks That Could Double Your Money. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the unstoppable stocks that could double your money. On March 19, Eledon report…
ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an upd…
* Eledon Pharmaceuticals press release [https://seekingalpha.com/pr/20445666-eledon-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-operating-and-financial] (ELDN [https://seekingalpha.com/symbol/ELDN]): FY GAAP EPS of -$0.52 bea…
Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b long-term extension study which continue…
[Type 1 diabetes concept suggested by insulin syringe] adrian825 * Eledon Pharmaceuticals (ELDN [https://seekingalpha.com/symbol/ELDN]) said that updated data on tegopribart, its candidate for type 1 diabetes patients undergoing allogeneic…
(RTTNews) - Several small- and mid-cap stocks posted notable gains in Wednesday's after-hours trading session, even though most companies did not release fresh news. The movement was largely driven by investor sentiment and sector momentum…
IRVINE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced preliminary results from an investigator-initiated trial conducted at the University of Chicago Medicine’s Transplant…
* Eledon Pharmaceuticals press release [https://seekingalpha.com/pr/20308730-eledon-pharmaceuticals-announces-recent-business-highlights-and-third-quarter-2025-financial] (ELDN [https://seekingalpha.com/symbol/ELDN]): Q3 GAAP EPS of -$0.21…
Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus Data supports advancement into Pha…
IRVINE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten public offering of (i) 15,152,485 shares of its common stock at a public offering pri…
Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m² Tegoprubart demonstrated a favorable safety and tolera…
IRVINE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the American Society of Nephrology’s upcoming Kidney Week 2025 Annual Meeting…
IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary session at the upcomi…
Biotech stocks can offer significant upside because they have high-growth potential if their drug candidates succeed in trials or gain FDA approval. For long-term biotech investors who can accept the risk of clinical-stage drugmakers, Eled…
IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Canto…
Key Points Earnings per share (GAAP) was $0.13 for Q2 2025, outperforming GAAP estimates for a loss of $0.23. Net loss (GAAP) fell to $11.2 million for Q2 2025, due to a significant gain from changes in warrant liabilities, despite researc…
* Eledon Pharmaceuticals press release [https://seekingalpha.com/pr/20201992-eledon-pharmaceuticals-reports-second-quarter-2025-operating-and-financial-results] (NASDAQ:ELDN [https://seekingalpha.com/symbol/ELDN]): Q2 GAAP EPS of -$0.13. *…
Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in ki…
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. [postmarket] AFTER HOURS GAINERS TICKER CHANGE COMM…
Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports tha…
[Stock Chart Between Skyscrapers - Financial Analysis, Trading, Investment] DKosig Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact…
IRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rej…
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 14th: Eledon Pharmaceuticals, Inc. ELDN: This clinical stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Co…
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Wipro Limited WIT: This information technology, consulting, and business process services company has seen the Zacks Consensus Estimate for its current year earnings…
Sernova (SVA.TO) on Wednesday said it signed a collaborative research agreement with Eledon Pharmace PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN…
IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will host an R&D Day in New York City on Wednesday, July 9, 2025 beginning at 8:30 am ET. The event will featu…
On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transplant of a genetically modified pig kidney…